Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study P-ICE
2006-006004-11Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Nov 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide, carboplatin and etoposide in Germ Cell Carcinoma, sponsored by Martin Luther University Halle-Wittenberg. Primary endpoints: Event-free survival at 1 year and Response rate. Started Nov 2007; status: completed.
02
Drugs
paclitaxelifosfamidecarboplatinetoposide
03
Conditions
Germ Cell Carcinoma
Beyond the preview
Go deeper on 2006-006004-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006004-11.